Abstract 50P
Background
As we enter an aging society, the number of elderly breast cancer patients is increasing. We assessed the prognostic factors of recurrence or metastasis for breast cancer patients over the age of 65 by analyzing the characteristics of tumor and long-term clinical outcomes.
Methods
Data were retrospectively analyzed for 286 breast cancer patients aged 65 years and older who underwent treatment in the Pusan national university hospital and Pusan national university Yangsan hospital from 2008 to 2014. Dividing two groups as the patients with event such as recurrence or metastasis and those who without it, the Cox regression model was used to examine the risk factors of recurrence or metastasis.
Results
Among 286 patients with invasive breast cancer, forty three patients (15.0%) have been found to have recurrence or distant metastasis during median follow-up period of 61 months. The poor prognosis was found in the advanced stage of breast cancer, patients without endocrine therapy and low Allred scores of estrogen receptor.Table: 50P
Variable | Hazard ratio | P-value | 95% CI |
---|---|---|---|
Stage | 1.78 | <0.0001 | (1.39, 2.28) |
Endocrine therapy | 0.04 | 0.0002 | (0.01, 0.23) |
Estrogen receptor | 1.34 | 0.0076 | (1.08, 1.66) |
Conclusions
The advanced stage of breast cancer was poor prognosis in the elderly breast cancer patients. Moreover, endocrine therapy should be performed on elderly breast cancer patients with high Allred score of estrogen receptor because it is good for prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract